Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1347)
The bill amends the Federal Food, Drug, and Cosmetic Act (section 505B/PREA) to add procedural due‑process steps before enforcement, limit penalties for drugs no longer marketed, increase FDA transparency about PREA penalties, and require guidance and a GAO study on pediatric requirements for orphan drugs. It also mandates FDA maintain automatic full‑waiver lists for certain adult diseases, preserves requirements for molecularly targeted pediatric cancer drugs, and permits NIH to reallocate up to 1% of pediatric research funds for specific pediatric research through 2030.
Progressive worries waiver lists reduce pediatric data availability.
Narrow health-policy focus with likely bipartisan appeal; modest industry concerns could be resolved in committee.
The bill amends the Federal Food, Drug, and Cosmetic Act (section 505B/PREA) to add procedural due‑process steps before enforcement, limit penalties for drugs no longer marketed, increase FDA transparency about PREA penalties, and require guidance and a GAO study on pediatric requirements for orphan drugs.
It also mandates FDA maintain automatic full‑waiver lists for certain adult diseases, preserves requirements for molecularly targeted pediatric cancer drugs, and permits NIH to reallocate up to 1% of pediatric research funds for specific pediatric research through 2030.
Targeted, technical pediatric reforms with modest fiscal impact and compromise features increase plausibility; industry concerns and procedural barriers are primary risks.
How solid the drafting looks.
Progressive worries waiver lists reduce pediatric data availability.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressive worries waiver lists reduce pediatric data availability.
Likely supportive of strengthening pediatric research and maintaining pediatric cancer safeguards, but wary about loosening requirements for orphan drugs.
Concerns center on automatic waiver lists and enforcement limits reducing pediatric labeling information.
Views the GAO study and transparency as useful oversight tools.
Views the bill as a pragmatic balance: it improves procedural fairness and transparency while clarifying orphan‑drug pediatric requirements.
Appreciates the public guidance, meeting, and GAO evaluation to inform policy.
Worries mainly about implementation detail and avoiding unintended weakening of pediatric data requirements.
Generally favorable: the bill adds procedural safeguards for sponsors, limits punitive actions for off‑market products, and clarifies orphan‑drug obligations, creating predictability.
The modest NIH funding flexibility is minor.
Overall, it reduces regulatory uncertainty and potential overreach.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted, technical pediatric reforms with modest fiscal impact and compromise features increase plausibility; industry concerns and procedural barriers are primary risks.
The bill has not accumulated any surfaced votes yet.
Progressive worries waiver lists reduce pediatric data availability.
Targeted, technical pediatric reforms with modest fiscal impact and compromise features increase plausibility; industry concerns and proced…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Innovation in Pediatric Drugs Act of 2025.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.